Huels Aktiengesellschaft

Huls Aktiengesellschaft

Fritz Schindler

Hugo Haemmerle

Frank Hill, Deceased

Jurgen Norden

Lutz Scheideler

Heinrich Aigner

Reinhard Samblebe

A transcutaneous medical device which has on its surface a fibrous material with free collagen fibers which are present in a natural structure. The transcutaneous medical device is prepared by applying to the surface of such a device a fibrous material with free collagen fibers present in a natural structure.

Medical device for improving skin fixation of indwelling catheters and

A dental implant coated with a composition containing desmodontal cells, where the cells are not propagated in vitro prior to being coated on the implant.

Biohybrid dental implant

A method of producing a mushroom aroma in mushroom cell masses. Heretofore, mushroom aromas have been produced nearly exclusively by using dried mushrooms or extracts from mushroom apothecia. Products from fermentatively cultured mushroom mycelium have thus far contained very little 1-octen-3-ol. According to the invention, fermentative cultured mushroom mycelium is mechanically treated in the presence of air, followed by contentration by known methods. Mushroom aromas are obtained in mushroom cell masses with high 1-octen-3-ol content, making the masses suitable for use in mushroom soups or mushroom sauces.

Method of producing a mushroom aroma in mushroom cell masses

L-malic acid is produced in a concentration of 170 to 400 g per liter and high yield by biotechnical conversion of fumaric acid neutralized with ammonium hydroxide in nutrient-free solution or suspension. Pure L-malic acid can be obtained economically therefrom with high efficiency in a quality suitable for food and pharmaceutical use. The fermentation can be carried out in simple vessels under non-sterile conditions. The conversion rate of the fumarate and the attainable concentration of L-malate are promoted by the ammonium ions.

Process for the bioconversion of fumarate to L-malate

Fertilizers containing urea with urease inhibitors, wherein the urease inhibitors are bromo-nitro compounds having the formula: ##STR1## wherein A.sub.1 is (CH.sub.2).sub.n.sbsb.1 X.sub.1, and A.sub.2 is (CH.sub.2).sub.n.sbsb.2 X.sub.2, wherein both n.sub.1 and n.sub.2 and X.sub.1 and X.sub.2 are the same or different, the alkyl groups of A.sub.1 and A.sub.2 are straigh-chain or branched-chain alkyl groups, and the substituents X.sub.1 and X.sub.2 are attached to any one of the carbon atoms of the alkyl groups, and n.sub.1 and n.sub.2 are 0 to 6, X.sub.1 and X.sub.2 are H or YR, wherein Y is --O--, --S-- or --NH-- and R is H or a straight or branched chain C.sub.1 -C.sub.6 alkyl, cyclopent(en)yl cyclohex(en)yl or phenyl group having one to three methyl groups or ##STR2## attached thereto, and R.sub.1 is H or a straight or branched chain C.sub.1 -C.sub.6 alkyl, cyclopent(en)yl or cyclohex(en)yl group having one to three methyl groups or ##STR3## attached thereto.

Growing community of inventors

Gelsenkirchen, Germany

Fritz Schindler